Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093259073> ?p ?o ?g. }
- W2093259073 endingPage "523" @default.
- W2093259073 startingPage "517" @default.
- W2093259073 abstract "PurposeTo prospectively investigate the efficacy and toxicity of accelerated hypofractionated thoracic radiation therapy (HypoTRT) combined with concurrent chemotherapy in the treatment of limited-stage small-cell lung cancer (LS-SCLC), with the hypothesis that both high radiation dose and short radiation time are important in this setting.Methods and MaterialsPatients with previously untreated LS-SCLC, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate organ function were eligible. HypoTRT of 55 Gy at 2.5 Gy per fraction over 30 days was given on the first day of the second or third cycle of chemotherapy. An etoposide/cisplatin regimen was given to 4 to 6 cycles. Patients who had a good response to initial treatment were offered prophylactic cranial irradiation. The primary endpoint was the 2-year progression-free survival rate.ResultsFifty-nine patients were enrolled from July 2007 through February 2012 (median age, 58 years; 86% male). The 2-year progression-free survival rate was 49.0% (95% confidence interval [CI] 35.3%-62.7%). Median survival time was 28.5 months (95% CI 9.0-48.0 months); the 2-year overall survival rate was 58.2% (95% CI 44.5%-71.9%). The 2-year local control rate was 76.4% (95% CI 63.7%-89.1%). The severe hematologic toxicities (grade 3 or 4) were leukopenia (32%), neutropenia (25%), and thrombocytopenia (15%). Acute esophagitis and pneumonitis of grade ≥3 occurred in 25% and 10% of the patients, respectively. Thirty-eight patients (64%) received prophylactic cranial irradiation.ConclusionOur study showed that HypoTRT of 55 Gy at 2.5 Gy per fraction daily concurrently with etoposide/cisplatin chemotherapy has favorable survival and acceptable toxicity. This radiation schedule deserves further investigation in LS-SCLC. To prospectively investigate the efficacy and toxicity of accelerated hypofractionated thoracic radiation therapy (HypoTRT) combined with concurrent chemotherapy in the treatment of limited-stage small-cell lung cancer (LS-SCLC), with the hypothesis that both high radiation dose and short radiation time are important in this setting. Patients with previously untreated LS-SCLC, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate organ function were eligible. HypoTRT of 55 Gy at 2.5 Gy per fraction over 30 days was given on the first day of the second or third cycle of chemotherapy. An etoposide/cisplatin regimen was given to 4 to 6 cycles. Patients who had a good response to initial treatment were offered prophylactic cranial irradiation. The primary endpoint was the 2-year progression-free survival rate. Fifty-nine patients were enrolled from July 2007 through February 2012 (median age, 58 years; 86% male). The 2-year progression-free survival rate was 49.0% (95% confidence interval [CI] 35.3%-62.7%). Median survival time was 28.5 months (95% CI 9.0-48.0 months); the 2-year overall survival rate was 58.2% (95% CI 44.5%-71.9%). The 2-year local control rate was 76.4% (95% CI 63.7%-89.1%). The severe hematologic toxicities (grade 3 or 4) were leukopenia (32%), neutropenia (25%), and thrombocytopenia (15%). Acute esophagitis and pneumonitis of grade ≥3 occurred in 25% and 10% of the patients, respectively. Thirty-eight patients (64%) received prophylactic cranial irradiation. Our study showed that HypoTRT of 55 Gy at 2.5 Gy per fraction daily concurrently with etoposide/cisplatin chemotherapy has favorable survival and acceptable toxicity. This radiation schedule deserves further investigation in LS-SCLC." @default.
- W2093259073 created "2016-06-24" @default.
- W2093259073 creator A5001959086 @default.
- W2093259073 creator A5005464911 @default.
- W2093259073 creator A5012818892 @default.
- W2093259073 creator A5020075019 @default.
- W2093259073 creator A5028895179 @default.
- W2093259073 creator A5032956681 @default.
- W2093259073 creator A5047138511 @default.
- W2093259073 creator A5061712616 @default.
- W2093259073 creator A5065195779 @default.
- W2093259073 creator A5065503019 @default.
- W2093259073 creator A5079873142 @default.
- W2093259073 date "2015-03-01" @default.
- W2093259073 modified "2023-10-16" @default.
- W2093259073 title "Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients With Limited-Stage Small-Cell Lung Cancer" @default.
- W2093259073 cites W1885320430 @default.
- W2093259073 cites W1961685780 @default.
- W2093259073 cites W1984254136 @default.
- W2093259073 cites W1986783484 @default.
- W2093259073 cites W1991585418 @default.
- W2093259073 cites W2002002528 @default.
- W2093259073 cites W2010674816 @default.
- W2093259073 cites W2011868684 @default.
- W2093259073 cites W2014364097 @default.
- W2093259073 cites W2020882823 @default.
- W2093259073 cites W2021987821 @default.
- W2093259073 cites W2026867617 @default.
- W2093259073 cites W2045359677 @default.
- W2093259073 cites W2049116330 @default.
- W2093259073 cites W2069592262 @default.
- W2093259073 cites W2078709072 @default.
- W2093259073 cites W2089609590 @default.
- W2093259073 cites W2115279758 @default.
- W2093259073 cites W2120046399 @default.
- W2093259073 cites W2127093828 @default.
- W2093259073 cites W2131664752 @default.
- W2093259073 cites W2138685162 @default.
- W2093259073 cites W2139248078 @default.
- W2093259073 cites W2146064654 @default.
- W2093259073 cites W2148791365 @default.
- W2093259073 cites W2151906910 @default.
- W2093259073 cites W2160012348 @default.
- W2093259073 cites W2323020638 @default.
- W2093259073 cites W3140025388 @default.
- W2093259073 doi "https://doi.org/10.1016/j.ijrobp.2014.09.042" @default.
- W2093259073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25481679" @default.
- W2093259073 hasPublicationYear "2015" @default.
- W2093259073 type Work @default.
- W2093259073 sameAs 2093259073 @default.
- W2093259073 citedByCount "30" @default.
- W2093259073 countsByYear W20932590732015 @default.
- W2093259073 countsByYear W20932590732016 @default.
- W2093259073 countsByYear W20932590732017 @default.
- W2093259073 countsByYear W20932590732018 @default.
- W2093259073 countsByYear W20932590732019 @default.
- W2093259073 countsByYear W20932590732020 @default.
- W2093259073 countsByYear W20932590732021 @default.
- W2093259073 countsByYear W20932590732022 @default.
- W2093259073 crossrefType "journal-article" @default.
- W2093259073 hasAuthorship W2093259073A5001959086 @default.
- W2093259073 hasAuthorship W2093259073A5005464911 @default.
- W2093259073 hasAuthorship W2093259073A5012818892 @default.
- W2093259073 hasAuthorship W2093259073A5020075019 @default.
- W2093259073 hasAuthorship W2093259073A5028895179 @default.
- W2093259073 hasAuthorship W2093259073A5032956681 @default.
- W2093259073 hasAuthorship W2093259073A5047138511 @default.
- W2093259073 hasAuthorship W2093259073A5061712616 @default.
- W2093259073 hasAuthorship W2093259073A5065195779 @default.
- W2093259073 hasAuthorship W2093259073A5065503019 @default.
- W2093259073 hasAuthorship W2093259073A5079873142 @default.
- W2093259073 hasBestOaLocation W20932590731 @default.
- W2093259073 hasConcept C126322002 @default.
- W2093259073 hasConcept C141071460 @default.
- W2093259073 hasConcept C168563851 @default.
- W2093259073 hasConcept C203092338 @default.
- W2093259073 hasConcept C2776256026 @default.
- W2093259073 hasConcept C2776283816 @default.
- W2093259073 hasConcept C2776694085 @default.
- W2093259073 hasConcept C2777063308 @default.
- W2093259073 hasConcept C2777714996 @default.
- W2093259073 hasConcept C2778119113 @default.
- W2093259073 hasConcept C2779134260 @default.
- W2093259073 hasConcept C2779524853 @default.
- W2093259073 hasConcept C2779562246 @default.
- W2093259073 hasConcept C2779920096 @default.
- W2093259073 hasConcept C2780873365 @default.
- W2093259073 hasConcept C2781413609 @default.
- W2093259073 hasConcept C43270747 @default.
- W2093259073 hasConcept C45393284 @default.
- W2093259073 hasConcept C500558357 @default.
- W2093259073 hasConcept C509974204 @default.
- W2093259073 hasConcept C71924100 @default.
- W2093259073 hasConcept C90924648 @default.
- W2093259073 hasConceptScore W2093259073C126322002 @default.
- W2093259073 hasConceptScore W2093259073C141071460 @default.
- W2093259073 hasConceptScore W2093259073C168563851 @default.
- W2093259073 hasConceptScore W2093259073C203092338 @default.